Walker B R, Ballard I M, Gold J A
J Int Med Res. 1977;5(2):85-90. doi: 10.1177/030006057700500202.
Mazindol is chemically unrelated to the phenethylamines and has not shown the side-effects or abuse potential of the amphetamine anorectics. To further define its potential for causing weight loss, a six-week double-blind placebo controlled study was undertaken in four centres. A common protocol was used except in one centre, behavioural modification also was employed, whereas in the other centres, no additional measures were used to cause weight loss. Two hundred and forty-five obese patients were assigned randomly to two mazindol groups and one placebo group in each centre. Ninety-eight and forty patients receiving mazindol and placebo respectively completed the protocol. The conclusions were: (a) no significant clinical or laboratory abnormalities occurred from mazindol therapy, (b) the placebo therapy patients did not lose weight without behavioural modification, (c) the placebo therapy group had a higher drop-out rate compared to the mazindol therapy group attributable to the patients' dissatisfaction with failure to lose weight, (d) mazindol therapy without behavioural modification and behavioural modification alone both resulted in a statistically significant mean weight loss of 1 pound/patient/week and (e) mazindol plus behavioural modification resulted in a greater mean weight loss of 1/2 pound/patient/week than with behavioural modification alone. Hence, mazindol is of value in the initial therapy of obesity.
马吲哚在化学结构上与苯乙胺类药物无关，且未表现出苯丙胺类食欲抑制剂的副作用或滥用可能性。为进一步明确其导致体重减轻的潜力，在四个中心开展了一项为期六周的双盲安慰剂对照研究。除一个中心外，所有中心均采用了通用方案，该中心还采用了行为矫正方法，而其他中心未采用额外措施来促进体重减轻。每个中心的245名肥胖患者被随机分为两个马吲哚组和一个安慰剂组。分别有98名接受马吲哚治疗的患者和40名接受安慰剂治疗的患者完成了研究方案。研究得出的结论如下：（a）马吲哚治疗未出现显著的临床或实验室异常情况；（b）未经行为矫正的安慰剂治疗患者体重未减轻；（c）与马吲哚治疗组相比，安慰剂治疗组的脱落率更高，原因是患者对未能减重不满意；（d）未采用行为矫正的马吲哚治疗和单纯行为矫正均使患者平均每周减重1磅，具有统计学意义；（e）马吲哚联合行为矫正导致的平均减重幅度大于单纯行为矫正，为患者平均每周减重1.5磅。因此，马吲哚在肥胖症的初始治疗中具有一定价值。
